FY2024 EPS Estimates for BioNTech SE (NASDAQ:BNTX) Reduced by Analyst

BioNTech SE (NASDAQ:BNTX - Free Report) - HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for BioNTech in a note issued to investors on Monday, August 19th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($3.66) for the year, down from their previous forecast of ($1.26). HC Wainwright has a "Buy" rating and a $113.00 price objective on the stock. The consensus estimate for BioNTech's current full-year earnings is ($2.04) per share. HC Wainwright also issued estimates for BioNTech's Q1 2025 earnings at ($2.36) EPS, Q2 2025 earnings at ($2.37) EPS and FY2025 earnings at ($3.11) EPS.

BNTX has been the topic of several other reports. Deutsche Bank Aktiengesellschaft upgraded shares of BioNTech from a "hold" rating to a "buy" rating and set a $95.00 price target on the stock in a research report on Wednesday, August 7th. TD Cowen lowered their target price on shares of BioNTech from $98.00 to $85.00 and set a "hold" rating on the stock in a report on Tuesday, August 6th. BMO Capital Markets cut their price target on shares of BioNTech from $123.00 to $122.00 and set an "outperform" rating for the company in a report on Tuesday, May 7th. Evercore ISI initiated coverage on shares of BioNTech in a report on Tuesday, May 14th. They set an "inline" rating and a $100.00 price objective for the company. Finally, HSBC raised BioNTech from a "hold" rating to a "buy" rating in a report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $109.09.

BioNTech Stock Performance

BNTX stock traded up $0.46 on Wednesday, reaching $88.99. 517,722 shares of the company were exchanged, compared to its average volume of 704,251. The firm has a market capitalization of $21.16 billion, a PE ratio of 177.98 and a beta of 0.23. BioNTech has a 12 month low of $76.53 and a 12 month high of $125.83. The stock's fifty day moving average price is $84.14 and its 200 day moving average price is $89.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.02) by ($1.34). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The business had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. During the same period last year, the business earned ($0.86) EPS. The business's quarterly revenue was down 23.3% compared to the same quarter last year.

Institutional Trading of BioNTech

Several institutional investors and hedge funds have recently added to or reduced their stakes in BNTX. GAMMA Investing LLC raised its stake in shares of BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company's stock worth $25,000 after buying an additional 150 shares during the last quarter. CWM LLC raised its position in shares of BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company's stock valued at $26,000 after acquiring an additional 217 shares during the last quarter. Frazier Financial Advisors LLC acquired a new position in shares of BioNTech in the 4th quarter valued at $30,000. First Horizon Advisors Inc. bought a new position in shares of BioNTech in the 4th quarter worth $38,000. Finally, Covestor Ltd grew its stake in shares of BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company's stock worth $38,000 after purchasing an additional 133 shares during the period. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.